共 50 条
- [31] Phase II, open-label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancerANTI-CANCER DRUGS, 2006, 17 (04) : 401 - 409Cufer, TaniaVrdoljak, EduardGaafar, RababErensoy, InciPemberton, Kristine
- [32] Clinical and biomarker analyses of sintilimab versus chemotherapy as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma: a randomized, open-label phase 2 study (ORIENT-2)Nature Communications, 13Jianming XuYi LiQingxia FanYongqian ShuLei YangTongjian CuiKangsheng GuMin TaoXiuwen WangChengxu CuiNong XuJuxiang XiaoQuanli GaoYunpeng LiuTao ZhangYuxian BaiWei LiYiping ZhangGuanghai DaiDong MaJingdong ZhangChunmei BaiYunchao HuangWangjun LiaoLin WuXi ChenYan YangJunye WangShoujian JiHui ZhouYan WangZhuo MaYanqi WangBo PengJiya SunChristoph Mancao
- [33] Clinical and biomarker analyses of sintilimab versus chemotherapy as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma: a randomized, open-label phase 2 study (ORIENT-2)NATURE COMMUNICATIONS, 2022, 13 (01)Xu, JianmingLi, YiFan, QingxiaShu, YongqianYang, LeiCui, TongjianGu, KangshengTao, MinWang, XiuwenCui, ChengxuXu, NongXiao, JuxiangGao, QuanliLiu, YunpengZhang, TaoBai, YuxianLi, WeiZhang, YipingDai, GuanghaiMa, DongZhang, JingdongBai, ChunmeiHuang, YunchaoLiao, WangjunWu, LinChen, XiYang, YanWang, JunyeJi, ShoujianZhou, HuiWang, YanMa, ZhuoWang, YanqiPeng, BoSun, JiyaMancao, Christoph
- [34] Efficacy and safety of second-line therapy with apatinib combined with chemotherapy as second-line therapy in advanced gastric cancer: a single-arm, open-label, prospective, multicenter studyANNALS OF TRANSLATIONAL MEDICINE, 2022, 10 (11)Zhang, YanXu, JunyingWang, QiongLing, GuohongMao, YongCai, MaohuaiYang, YangMei, JingfengHan, ZhengxiangFeng, JifengWu, YuanShi, LinWen, ShaodiShen, Bo
- [35] Open-label phase 2 trial of second-line everolimus in patients with metastatic renal cell carcinoma (mRCC)BJU INTERNATIONAL, 2012, 110 : 15 - 15Agarwala, S. S.Wang, J.Ye, D.Sallo, V.Stergiopoulos, S. G.Brechenmacher, T.Motzer, R. J.
- [36] Pembrolizumab versus paclitaxel as second-line therapy for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Phase 3 KEYNOTE-061 study.JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)Ohtsu, AtsushiTabernero, JosepBang, Yung-JueFuchs, Charles S.Sun, LindaWang, ZhenCsiki, IldikoKoshiji, MinoriVan Cutsem, Eric
- [37] Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trialLANCET ONCOLOGY, 2021, 22 (07): : 931 - 945Powles, ThomasCsoszi, TiborOzguroglu, MustafaMatsubara, NobuakiGeczi, LajosCheng, Susanna Y-SFradet, YvesOudard, StephaneVulsteke, ChristofBarrera, Rafael MoralesFlechon, AudeGunduz, SeydaLoriot, YohannRodriguez-Vida, AlejoMamtani, RonacYu, Evan Y.Nam, KijoengImai, KentaroMoreno, Blanca HometAlva, Ajjai
- [38] Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 studyLANCET ONCOLOGY, 2020, 21 (06): : 832 - 842Huang, JingXu, JianmingChen, YunZhuang, WuZhang, YipingChen, ZhendongChen, JiaZhang, HelongNiu, ZuoxingFan, QingxiaLin, LizhuGu, KangshengLiu, YingBa, YiMiao, ZhanhuiJiang, XiaodongZeng, MingChen, JianhuaFu, ZhichaoGan, LuWang, JunZhan, XianbaoLiu, TianshuLi, ZhipingShen, LinShu, YongqianZhang, TaoYang, QingZou, Jianjun
- [39] Pembrolizumab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced esophageal cancer: The phase 3 KEYNOTE-590 studyANNALS OF ONCOLOGY, 2020, 31 : S1192 - S1193Kato, K.Sun, J-M.Shah, M. A.Enzinger, P. C.Adenis, A.Doi, T.Kojima, T.Metges, J-P.Li, Z.Kim, S-B.Cho, B. C. ChulMansoor, W.Li, S-H.Sunpaweravong, P.Maqueda, M. A.Goekkurt, E.Liu, Q.Shah, S.Bhagia, P.Shen, L.
- [40] Evaluating Alternative Ramucirumab Doses as a Single Agent or with Paclitaxel in Second-Line Treatment of Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma: Results from Two Randomized, Open-Label, Phase II StudiesCANCERS, 2022, 14 (05)Shah, Manish A.Udrea, Anghel AdrianBondarenko, IgorMansoor, WasSanchez, Raquel GuardenoSarosiek, TomaszBozzarelli, SilviaSchenker, MichaelGomez-Martin, CarlosMorgan, Carysoezgueroglu, MustafaPikiel, JoannaKalofonos, Haralabos P.Wojcik, ElzbietaBuchler, TomasSwinson, DanielCicin, IrfanJoseph, ManoVynnychenko, IhorLuft, Alexander ValerievichEnzinger, Peter C.Salek, TomasPapandreou, ChristosTournigand, ChristopheMaiello, EvaristoWei, RanFerry, DavidGao, LingOliveira, Joana M.Ajani, Jaffer A.